Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 2/20 | 0.51 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.51 |
| ▸ | CHUK | O15111 | 3/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.43 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.42 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590787 | 0.84 | CHUK (0.48) | MAP3K7TAB1CHUKHSP90AB1ROCK2 | |
| SCHEMBL21818811 | 0.79 | LIMK1 (0.47) | ROCK2JAK3LIMK1LIMK2AKT1 | |
| SCHEMBL31133380 | 0.79 | LIMK1 (0.47) | ROCK2JAK3LIMK1LIMK2AKT1 | |
| SCHEMBL12590782 | 0.78 | NOTUM (0.49) | MAP3K7TAB1JAK3AKT1 | |
| SCHEMBL14649086 | 0.73 | MAP3K7 (0.56) | MAP3K7TAB1CHUKHSP90AB1ROCK2 | |
| Toyocamycin Aglycone SCHEMBL7698538 | 0.72 | MAP3K7 (0.54) | MAP3K7TAB1CHUKHSP90AB1ROCK2 | |
| SCHEMBL27226221 | 0.71 | GAA (0.40) | — | |
| SCHEMBL19185239 | 0.71 | MAP3K7 (0.54) | MAP3K7TAB1CHUKHSP90AB1ROCK2 | |
| SCHEMBL154683 | 0.70 | CHUK (0.61) | MAP3K7TAB1CHUKHSP90AB1ROCK2 | |
| SCHEMBL17401156 | 0.70 | MAP3K7 (0.56) | MAP3K7TAB1CHUKHSP90AB1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113354650-B | Preparation method of 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine-5-carbonitrile | 安徽大学 | 2023-12-19 | — | — | CN | disclosed |
| CN-113354650-A | Preparation method of 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine-5-carbonitrile | 安徽大学 | 2021-09-07 | — | — | CN | disclosed |
| US-7968536-B2 | Heterocyclic compounds useful as RAF kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968536-B2 | Heterocyclic compounds useful as RAF kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2009006404-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | BRAF, RAF1, ARAF | MAP3K7 27/4885TAB1 637/4885CHUK 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.